Literature DB >> 8386741

Characterization of a novel Hodgkin cell line, HD-MyZ, with myelomonocytic features mimicking Hodgkin's disease in severe combined immunodeficient mice.

R C Bargou1, M Y Mapara, C Zugck, P T Daniel, M Pawlita, H Döhner, B Dörken.   

Abstract

A novel Hodgkin cell line, designated HD-MyZ, was established from the pleural effusion of a 29-yr-old patient with Hodgkin's disease (HD) of nodular sclerosing type. The majority of cells grow adherently and display typical morphological characteristics of Reed-Sternberg (RS) and Hodgkin (H) cells, i.e., large multi- and mononucleated cells with prominent nucleoli. Immunofluorescence analysis revealed a myelomonocytoid immunophenotype (expression of CD13 and CD68, and lack of lymphoid markers). HD-MyZ cells strongly expressed restin, a recently described intermediate filament-associated protein, the expression of which is restricted to H cells, RS cells, and in vitro cultivated peripheral blood monocytes. In addition mRNA expression of c-fms (colony-stimulating factor 1 receptor) could be induced in HD-MyZ cells by phorbol myristate acetate (PMA) stimulation. Southern blot analysis did not detect rearrangement of T cell receptor beta and immunoglobulin H loci, thus demonstrating the lack of lymphoid commitment. HD-MyZ cells were also devoid of Epstein-Barr virus genomes. HD-MyZ cells constitutively express mRNAs for interleukin 1 alpha (IL-1 alpha), IL-1 beta, IL-5, IL-6, IL-7, IL-8, IL-10, IL-1 receptor (type I), and IL-6 receptor. Stimulation of cells with PMA increased mRNA expression as well as the secretion of IL-1 beta, IL-6, and IL-8, and induced the de novo expression of IL-8 receptors. Xenotransplantation into severe combined immunodeficient (SCID) mice by intravenous or subcutaneous inoculation led to development of disseminated tumors with infiltrative and destructive growth. In addition lymphadenopathy, pleural effusion, and infiltration of spleen were observed. Morphological and immunological analysis of tumor cells revealed the same features as HD-MyZ cells. This cell line might be an important tool for understanding the pathogenesis and biology of HD. In addition the SCID mice model might prove helpful in developing new therapeutic strategies.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8386741      PMCID: PMC2191008          DOI: 10.1084/jem.177.5.1257

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  55 in total

1.  Phenotype versus immunoglobulin and T-cell receptor genotype of Hodgkin-derived cell lines: activation of immature lymphoid cells in Hodgkin's disease.

Authors:  M H Falk; H Tesch; H Stein; V Diehl; D B Jones; C Fonatsch; G W Bornkamm
Journal:  Int J Cancer       Date:  1987-08-15       Impact factor: 7.396

2.  Cloning of cDNA for human T-cell replacing factor (interleukin-5) and comparison with the murine homologue.

Authors:  C Azuma; T Tanabe; M Konishi; T Kinashi; T Noma; F Matsuda; Y Yaoita; K Takatsu; L Hammarström; C I Smith
Journal:  Nucleic Acids Res       Date:  1986-11-25       Impact factor: 16.971

3.  Expression of interleukin-1 in Reed-Sternberg cells and neoplastic cells from true histiocytic malignancies.

Authors:  S M Hsu; X Zhao
Journal:  Am J Pathol       Date:  1986-11       Impact factor: 4.307

4.  Human c-myb protooncogene: nucleotide sequence of cDNA and organization of the genomic locus.

Authors:  B Majello; L C Kenyon; R Dalla-Favera
Journal:  Proc Natl Acad Sci U S A       Date:  1986-12       Impact factor: 11.205

5.  Primary structure of the human fgr proto-oncogene product p55c-fgr.

Authors:  S Katamine; V Notario; C D Rao; T Miki; M S Cheah; S R Tronick; K C Robbins
Journal:  Mol Cell Biol       Date:  1988-01       Impact factor: 4.272

6.  Phenotypic and genotypic analysis of Hodgkin's disease derived cell lines: histopathological and clinical implications.

Authors:  V Diehl; M Pfreundschuh; C Fonatsch; H Stein; M Falk; H Burrichter; M Schaadt
Journal:  Cancer Surv       Date:  1985

7.  cDNA cloning of IL-1 alpha and IL-1 beta from mRNA of U937 cell line.

Authors:  T Nishida; N Nishino; M Takano; K Kawai; K Bando; Y Masui; S Nakai; Y Hirai
Journal:  Biochem Biophys Res Commun       Date:  1987-02-27       Impact factor: 3.575

8.  Sensitive, high-resolution chromatin and chromosome mapping in situ: presence and orientation of two closely integrated copies of EBV in a lymphoma line.

Authors:  J B Lawrence; C A Villnave; R H Singer
Journal:  Cell       Date:  1988-01-15       Impact factor: 41.582

9.  Restin: a novel intermediate filament-associated protein highly expressed in the Reed-Sternberg cells of Hodgkin's disease.

Authors:  G Bilbe; J Delabie; J Brüggen; H Richener; F A Asselbergs; N Cerletti; C Sorg; K Odink; L Tarcsay; W Wiesendanger
Journal:  EMBO J       Date:  1992-06       Impact factor: 11.598

10.  Human proto-oncogene c-kit: a new cell surface receptor tyrosine kinase for an unidentified ligand.

Authors:  Y Yarden; W J Kuang; T Yang-Feng; L Coussens; S Munemitsu; T J Dull; E Chen; J Schlessinger; U Francke; A Ullrich
Journal:  EMBO J       Date:  1987-11       Impact factor: 11.598

View more
  11 in total

1.  The transcription factor PU.1, necessary for B-cell development is expressed in lymphocyte predominance, but not classical Hodgkin's disease.

Authors:  E Torlakovic; A Tierens; H D Dang; J Delabie
Journal:  Am J Pathol       Date:  2001-11       Impact factor: 4.307

2.  Compatible-solute-supported periplasmic expression of functional recombinant proteins under stress conditions.

Authors:  S Barth; M Huhn; B Matthey; A Klimka; E A Galinski; A Engert
Journal:  Appl Environ Microbiol       Date:  2000-04       Impact factor: 4.792

3.  Constitutive nuclear factor-kappaB-RelA activation is required for proliferation and survival of Hodgkin's disease tumor cells.

Authors:  R C Bargou; F Emmerich; D Krappmann; K Bommert; M Y Mapara; W Arnold; H D Royer; E Grinstein; A Greiner; C Scheidereit; B Dörken
Journal:  J Clin Invest       Date:  1997-12-15       Impact factor: 14.808

4.  Hodgkin lymphoma therapy with interleukin-4 receptor-directed cytotoxin in an infiltrating animal model.

Authors:  Mariko Kawakami; Koji Kawakami; Mitomu Kioi; Pamela Leland; Raj K Puri
Journal:  Blood       Date:  2004-12-30       Impact factor: 22.113

5.  Interleukin-8 in Hodgkin's disease. Preferential expression by reactive cells and association with neutrophil density.

Authors:  H D Foss; H Herbst; S Gottstein; G Demel; I Araujó; H Stein
Journal:  Am J Pathol       Date:  1996-04       Impact factor: 4.307

Review 6.  Immunodeficient mouse models of lymphoid tumors.

Authors:  Kazunori Imada
Journal:  Int J Hematol       Date:  2003-05       Impact factor: 2.490

7.  Hodgkin disease: Hodgkin and Reed-Sternberg cells picked from histological sections show clonal immunoglobulin gene rearrangements and appear to be derived from B cells at various stages of development.

Authors:  R Küppers; K Rajewsky; M Zhao; G Simons; R Laumann; R Fischer; M L Hansmann
Journal:  Proc Natl Acad Sci U S A       Date:  1994-11-08       Impact factor: 11.205

8.  Genome wide analysis of acute myeloid leukemia reveal leukemia specific methylome and subtype specific hypomethylation of repeats.

Authors:  Marwa H Saied; Jacek Marzec; Sabah Khalid; Paul Smith; Thomas A Down; Vardhman K Rakyan; Gael Molloy; Manoj Raghavan; Silvana Debernardi; Bryan D Young
Journal:  PLoS One       Date:  2012-03-29       Impact factor: 3.240

9.  Diverse hematological malignancies including hodgkin-like lymphomas develop in chimeric MHC class II transgenic mice.

Authors:  Silke H Raffegerst; Gabriele Hoelzlwimmer; Sandra Kunder; Josef Mysliwietz; Leticia Quintanilla-Martinez; Dolores J Schendel
Journal:  PLoS One       Date:  2009-12-31       Impact factor: 3.240

10.  Dendritic cells initiate immune control of epstein-barr virus transformation of B lymphocytes in vitro.

Authors:  Kara Bickham; Kiera Goodman; Casper Paludan; Sarah Nikiforow; Ming Li Tsang; Ralph M Steinman; Christian Münz
Journal:  J Exp Med       Date:  2003-12-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.